Evaluation of pharmacokinetic/pharmacodynamic relationships of PD-0162819, a biotin carboxylase inhibitor representing a new class of antibacterial compounds, using in vitro infection models.

The present study investigated the pharmacokinetic/pharmacodynamic (PK/PD) relationships of a prototype biotin carboxylase (BC) inhibitor, PD-0162819, against Haemophilus influenzae 3113 in static concentration time-kill (SCTK) and one-compartment chemostat in vitro infection models. H. influenzae 3113 was exposed to PD-0162819 concentrations of 0.5 to 16× the MIC (MIC = 0.125 µg/ml) and area-under-the-curve (AUC)/MIC ratios of 1 to 1,100 in SCTK and chemostat experiments, respectively. Serial samples were collected over 24 h. For efficacy driver analysis, a sigmoid maximum-effect (E(max)) model was fitted to the relationship between bacterial density changes over 24 h and corresponding PK/PD indices. A semimechanistic PK/PD model describing the time course of bacterial growth and death was developed. The AUC/MIC ratio best explained efficacy (r(2) = 0.95) compared to the peak drug concentration (C(max))/MIC ratio (r(2) = 0.76) and time above the MIC (T>MIC) (r(2) = 0.88). Static effects and 99.9% killing were achieved at AUC/MIC values of 500 and 600, respectively. For time course analysis, the net bacterial growth rate constant, maximum bacterial density, and maximum kill rate constant were similar in SCTK and chemostat studies, but PD-0162819 was more potent in SCTK than in the chemostat (50% effective concentration [EC(50)] = 0.046 versus 0.34 µg/ml). In conclusion, basic PK/PD relationships for PD-0162819 were established using in vitro dynamic systems. Although the bacterial growth parameters and maximum drug effects were similar in SCTK and the chemostat system, PD-0162819 appeared to be more potent in SCTK, illustrating the importance of understanding the differences in preclinical models. Additional studies are needed to determine the in vivo relevance of these results.

Raman chemical mapping of low-content active pharmaceutical ingredient formulations. III. Statistically optimized sampling and detection of polymorphic forms in tablets on stability.

Several tablets of a formulation containing 1% w/w of the desired active pharmaceutical ingredient (API) form are spiked with minimal amounts of two different anhydrous polymorphs and an amorphous form. The amount of contaminant form was 2.5 to 10% of the total API concentration (0.025 to 0.1% w/w in the tablet), with five spiked tablets prepared. The presence of these contaminant particles are then identified using Raman microscopy/mapping. The entire surface of each of these tablets is Raman-probed through a grid based on our previous proposal (Sasic, S.; Whitlock, M. Appl. Spectrosc.2008, 62, 916) about the minimal number of spectra to acquire that would guarantee identification of the targeted component (taking into account the limit of detection). All three forms have been clearly identified in the Raman mapping spectra of prepared "calibration" tablets; particularly of note is the 2.5% spike (0.025% w/w in the tablet) of the relatively weakly scattering amorphous form. The same method is then applied to packaged tablets on stability and demonstrates that none of the previously analyzed contaminant forms is detected, hence building confidence that the desired API form does not change during stability testing.

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore.

As the need for novel antibiotic classes to combat bacterial drug resistance increases, the paucity of leads resulting from target-based antibacterial screening of pharmaceutical compound libraries is of major concern. One explanation for this lack of success is that antibacterial screening efforts have not leveraged the eukaryotic bias resulting from more extensive chemistry efforts targeting eukaryotic gene families such as G protein-coupled receptors and protein kinases. Consistent with a focus on antibacterial target space resembling these eukaryotic targets, we used whole-cell screening to identify a series of antibacterial pyridopyrimidines derived from a protein kinase inhibitor pharmacophore. In bacteria, the pyridopyrimidines target the ATP-binding site of biotin carboxylase (BC), which catalyzes the first enzymatic step of fatty acid biosynthesis. These inhibitors are effective in vitro and in vivo against fastidious gram-negative pathogens including Haemophilus influenzae. Although the BC active site has architectural similarity to those of eukaryotic protein kinases, inhibitor binding to the BC ATP-binding site is distinct from the protein kinase-binding mode, such that the inhibitors are selective for bacterial BC. In summary, we have discovered a promising class of potent antibacterials with a previously undescribed mechanism of action. In consideration of the eukaryotic bias of pharmaceutical libraries, our findings also suggest that pursuit of a novel inhibitor leads for antibacterial targets with active-site structural similarity to known human targets will likely be more fruitful than the traditional focus on unique bacterial target space, particularly when structure-based and computational methodologies are applied to ensure bacterial selectivity.

Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine.

Solution-mediated phase transformation (SMPT) has been used as a focused technique to rapidly identify the stable polymorph of a given substance. Despite ample precedence for acetonitrile being a good solvent for SMPT of sulfamerazine (SMZ), samples from specific lots of SMZ failed to convert from Form I to Form II after suspension for 2 weeks in acetonitrile. In these lots, an acetyl derivative of SMZ was identified and shown to impede transformation to the stable polymorph. The inhibitory effect of this impurity on polymorphic conversion was overcome with practical adjustments to experimental procedure, which hastened the kinetics of SMPT. The critical factors considered were (1) modifying the solvent to increase solubility, (2) minimizing the level of impurity in the slurries, (3) pre-treatment of the solid to quickly reach maximum supersaturation, and (4) temperatures that optimized kinetics as well as the free energy difference between enantiotropically related polymorphs.

Statistical analysis of differences in the Raman spectra of polymorphs.

Raman spectroscopy is a useful tool for identifying polymorphs of pharmaceutical compounds. One limitation of the technique is that the small differences in Raman spectra require confirmation of polymorphs by other methods. Fourteen compounds, both commercial and proprietary pharmaceutical compounds and their polymorphs, were analyzed by Raman microscopy. By using descriptive statistics and analysis of variance (ANOVA), several methods are proposed that provide an approach for comparing the spectra of suspected polymorphs. Because it is difficult to determine the exact amount that a peak may shift before two forms should be considered different; a guideline of a shift greater than 1.6/cm(-1) is proposed. A standard ANOVA analysis is used to compare individual peaks both within and between polymorphs, as well as an alternative method that proposes the use of a total ANOVA table that considers the entire spectrum. Both methods have their advantages and disadvantages, but they provide a starting point for the comparison of a large number of spectra, and effectively differentiate between polymorphs of a given compound. The method accurately identified true polymorphs in all cases, but showed a bias towards misidentifying some samples as polymorphs when they were in fact the same form. This bias was not significant and even in these situations, the magnitude of the calculated F values was a useful indicator of whether the result was a false positive or not.